Your browser doesn't support javascript.
loading
A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
Rhee, E J; Lee, W Y; Yoon, K H; Yoo, S J; Lee, I K; Baik, S H; Kim, Y K; Lee, M K; Park, K S; Park, J Y; Cha, B S; Lee, H W; Min, K W; Bae, H Y; Kim, M J; Kim, J A; Kim, D K; Kim, S W.
Affiliation
  • Rhee EJ; Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Diabetes Obes Metab ; 12(12): 1113-9, 2010 Dec.
Article in En | MEDLINE | ID: mdl-20977584
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organic Chemicals / Glycated Hemoglobin / Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2010 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organic Chemicals / Glycated Hemoglobin / Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2010 Document type: Article